Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL6262884 | 0.97 | TP53 (0.44) | — | |
| L-Lactic Acid SCHEMBL30837306 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL1331114 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL27943629 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL1332699 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL30913243 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL4360 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL186171 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL1333089 | 0.96 | — | — | |
| L-Lactic Acid SCHEMBL7999572 | 0.96 | TP53 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109753-A1 | Syntac Polypeptides and Uses Thereof | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260097127-A1 | Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260070959-A1 | T-Cell Modulatory Chimeric Molecules and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260049116-A1 | T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof | CUE BIOPHARMA INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4691566-A2 | TGF-BETA POLYPEPTIDES | Cue Biopharma, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12534527-B2 | KIR3DL3 is an inhibitory receptor of the immune system and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-01-27 | — | — | US | disclosed |
| US-12528850-B2 | TGF-β polypeptides | CUE BIOPHARMA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12485184-B2 | Multimeric T-cell modulatory polypeptides and methods of use thereof | CUE BIOPHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12485183-B2 | Multimeric T-cell modulatory polypeptides and methods of use thereof | CUE BIOPHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250352634-A1 | Coxsackievirus B Compositions and Methods Of Use Thereof | VACTECH OY (FI) | 2025-11-20 | — | — | US | disclosed |
| US-20220089680-A1 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089681-A1 | METHODS FOR MODULATING AN IMMUNE RESPONSE | CUE BIOPHARMA, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2022056014-A1 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022056015-A1 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220079985-A1 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20210299074-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | PURDUE RESEARCH FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210299073-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | PURDUE RESEARCH FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-11065216-B2 | Compositions and methods for regulating body weight and metabolic syndromes | PURDUE RESEARCH FOUNDATION (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3541426-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | Purdue Research Foundation (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093966-A1 | COMPOSITIONS AND METHODS FOR REGULATING BODY WEIGHT AND METABOLIC SYNDROMES | PURDUE RESEARCH FOUNDATION (US) | 2018-05-24 | — | — | WO | disclosed |